140 related articles for article (PubMed ID: 32022480)
1. A Combinatorial Virtual Screening Approach Driving the Synthesis of 2,4-Thiazolidinedione-Based Molecules as New Dual mPGES-1/5-LO Inhibitors.
Lauro G; Terracciano S; Cantone V; Ruggiero D; Fischer K; Pace S; Werz O; Bruno I; Bifulco G
ChemMedChem; 2020 Mar; 15(6):481-489. PubMed ID: 32022480
[TBL] [Abstract][Full Text] [Related]
2. Structure-based screening for the discovery of 1,2,4-oxadiazoles as promising hits for the development of new anti-inflammatory agents interfering with eicosanoid biosynthesis pathways.
Potenza M; Sciarretta M; Chini MG; Saviano A; Maione F; D'Auria MV; De Marino S; Giordano A; Hofstetter RK; Festa C; Werz O; Bifulco G
Eur J Med Chem; 2021 Nov; 224():113693. PubMed ID: 34315041
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel microsomal prostaglandin E
Lauro G; Manfra M; Pedatella S; Fischer K; Cantone V; Terracciano S; Bertamino A; Ostacolo C; Gomez-Monterrey I; De Nisco M; Riccio R; Novellino E; Werz O; Campiglia P; Bifulco G
Eur J Med Chem; 2017 Jan; 125():278-287. PubMed ID: 27688183
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E
Cheung SY; Werner M; Esposito L; Troisi F; Cantone V; Liening S; König S; Gerstmeier J; Koeberle A; Bilancia R; Rizza R; Rossi A; Roviezzo F; Temml V; Schuster D; Stuppner H; Schubert-Zsilavecz M; Werz O; Hanke T; Pace S
Eur J Med Chem; 2018 Aug; 156():815-830. PubMed ID: 30053720
[TBL] [Abstract][Full Text] [Related]
5. Simple heteroaryl modifications in the 4,5-diarylisoxazol-3-carboxylic acid scaffold favorably modulates the activity as dual mPGES-1/5-LO inhibitors with in vivo efficacy.
Gürses T; Olğaç A; Garscha U; Gür Maz T; Bal NB; Uludağ O; Çalışkan B; Schubert US; Werz O; Banoglu E
Bioorg Chem; 2021 Jul; 112():104861. PubMed ID: 33826984
[TBL] [Abstract][Full Text] [Related]
6. Lipophilic extracts of Leucas zeylanica, a multi-purpose medicinal plant in the tropics, inhibit key enzymes involved in inflammation and gout.
Napagoda M; Gerstmeier J; Butschek H; Lorenz S; Kanatiwela D; Qader M; Nagahawatte A; De Soyza S; Wijayaratne GB; Svatoš A; Jayasinghe L; Koeberle A; Werz O
J Ethnopharmacol; 2018 Oct; 224():474-481. PubMed ID: 29727733
[TBL] [Abstract][Full Text] [Related]
7. A Multi-step Virtual Screening Protocol for the Identification of Novel Non-acidic Microsomal Prostaglandin E
Shekfeh S; Çalışkan B; Fischer K; Yalçın T; Garscha U; Werz O; Banoglu E
ChemMedChem; 2019 Jan; 14(2):273-281. PubMed ID: 30537167
[TBL] [Abstract][Full Text] [Related]
8. A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold.
Hieke M; Greiner C; Thieme TM; Schubert-Zsilavecz M; Werz O; Zettl H
Bioorg Med Chem Lett; 2011 Mar; 21(5):1329-33. PubMed ID: 21310608
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
Svouraki A; Garscha U; Kouloura E; Pace S; Pergola C; Krauth V; Rossi A; Sautebin L; Halabalaki M; Werz O; Gaboriaud-Kolar N; Skaltsounis AL
J Nat Prod; 2017 Mar; 80(3):699-706. PubMed ID: 28240894
[TBL] [Abstract][Full Text] [Related]
10. Natural products as inhibitors of prostaglandin E
Koeberle A; Werz O
Biotechnol Adv; 2018 Nov; 36(6):1709-1723. PubMed ID: 29454981
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin.
Schaible AM; Traber H; Temml V; Noha SM; Filosa R; Peduto A; Weinigel C; Barz D; Schuster D; Werz O
Biochem Pharmacol; 2013 Aug; 86(4):476-86. PubMed ID: 23623753
[TBL] [Abstract][Full Text] [Related]
12. Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions.
Koeberle A; Laufer SA; Werz O
J Med Chem; 2016 Jul; 59(13):5970-86. PubMed ID: 26791385
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of novel myrtucommulones and structural analogues that target mPGES-1 and 5-lipoxygenase.
Wiechmann K; Müller H; Huch V; Hartmann D; Werz O; Jauch J
Eur J Med Chem; 2015 Aug; 101():133-49. PubMed ID: 26123643
[TBL] [Abstract][Full Text] [Related]
14. Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents.
De Simone R; Chini MG; Bruno I; Riccio R; Mueller D; Werz O; Bifulco G
J Med Chem; 2011 Mar; 54(6):1565-75. PubMed ID: 21323313
[TBL] [Abstract][Full Text] [Related]
15. Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation.
Bruno F; Errico S; Pace S; Nawrozkij MB; Mkrtchyan AS; Guida F; Maisto R; Olgaç A; D'Amico M; Maione S; De Rosa M; Banoglu E; Werz O; Fiorentino A; Filosa R
Eur J Med Chem; 2018 Jul; 155():946-960. PubMed ID: 30015253
[TBL] [Abstract][Full Text] [Related]
16. Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone.
Larsson K; Steinmetz J; Bergqvist F; Arefin S; Spahiu L; Wannberg J; Pawelzik SC; Morgenstern R; Stenberg P; Kublickiene K; Korotkova M; Jakobsson PJ
Br J Pharmacol; 2019 Dec; 176(24):4625-4638. PubMed ID: 31404942
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore modeling and virtual screening for novel acidic inhibitors of microsomal prostaglandin E₂ synthase-1 (mPGES-1).
Waltenberger B; Wiechmann K; Bauer J; Markt P; Noha SM; Wolber G; Rollinger JM; Werz O; Schuster D; Stuppner H
J Med Chem; 2011 May; 54(9):3163-74. PubMed ID: 21466167
[TBL] [Abstract][Full Text] [Related]
18. Common structural and pharmacophoric features of mPGES-1 and LTC4S.
Devi NS; Paragi-Vedanthi P; Bender A; Doble M
Future Med Chem; 2018 Feb; 10(3):259-268. PubMed ID: 29355395
[TBL] [Abstract][Full Text] [Related]
19. Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition.
Hanke T; Lamers C; Gomez RC; Schneider G; Werz O; Schubert-Zsilavecz M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3757-63. PubMed ID: 25037914
[TBL] [Abstract][Full Text] [Related]
20. Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP).
Ho JD; Lee MR; Rauch CT; Aznavour K; Park JS; Luz JG; Antonysamy S; Condon B; Maletic M; Zhang A; Hickey MJ; Hughes NE; Chandrasekhar S; Sloan AV; Gooding K; Harvey A; Yu XP; Kahl SD; Norman BH
Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129800. PubMed ID: 33246032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
